A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Warns That Robotic Surgery May Lower Life Expectancy for Breast... March 1, 2019 “Scars are Tattoos with Better Stories” July 21, 2021 TRACERx: Using blood tests to track lung cancer May 1, 2023 FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... Celebrating 10 years of partnership with NIVEA Sun Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types...
